Oncology experts from the University of Kansas discuss the evolving role of neoadjuvant/perioperative immunotherapy in resectable stage-III NSCLC, analyzing recent trial data and addressing the nuanced factors that inform their decisions between neoadjuvant and perioperative treatments in clinical practice.
Zenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.